Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.53 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414768 | 0.82 | TGFBR1 (0.53) | TGFBR1TGFBR2CYP3A4CYP2C8CCR1 | |
| SCHEMBL3724250 | 0.78 | TGFBR1 (0.53) | TGFBR1TGFBR2CCR1CCR8METAP2 | |
| SCHEMBL4157010 | 0.74 | TGFBR1 (0.56) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL27808408 | 0.73 | TGFBR1 (0.43) | TGFBR1TGFBR2CYP3A4CYP2C8CCR1 | |
| SCHEMBL4150343 | 0.73 | TGFBR1 (0.58) | TGFBR1TGFBR2CYP3A4CYP2C8MAPK14 | |
| SCHEMBL3723221 | 0.73 | TGFBR1 (0.50) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL3722830 | 0.73 | TGFBR1 (0.50) | TGFBR1TGFBR2CYP3A4CYP2C8MAPK14 | |
| SCHEMBL4165337 | 0.72 | TGFBR1 (0.52) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL12040846 | 0.72 | ADORA2A (0.42) | TGFBR1CYP3A4CYP2C8ADORA2AADORA1 | |
| SCHEMBL3722185 | 0.72 | TGFBR1 (0.48) | TGFBR1TGFBR2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539338-A1 | NOVEL MICROBICIDES | Syngenta Participations AG (CH) | 2013-01-02 | — | — | EP | claimed |
| US-20120316184-A1 | NOVEL MICROBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-12-13 | — | — | US | claimed |
| CN-102770433-A | Novel microbicides | SYNGENTA PARTICIPATIONS A G | 2012-11-07 | — | — | CN | claimed |
| WO-2011104183-A1 | NOVEL MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-01 | — | — | WO | claimed |
| EP-2539338-A1 | NOVEL MICROBICIDES | Syngenta Participations AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316184-A1 | NOVEL MICROBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| CN-102770433-A | Novel microbicides | SYNGENTA PARTICIPATIONS A G | 2012-11-07 | — | — | CN | disclosed |
| WO-2011104183-A1 | NOVEL MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885TGFBR2 443/4885CYP3A4 111/4885 |
| US-20120316184-A1 | NOVEL MICROBICIDES | NOX1, MSR1, FPR1 | TGFBR1 1674/4885TGFBR2 3090/4885CYP3A4 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.